Evidence map›Paper›PMID 26099603›Full record

SynthesisClinical rheumatology2016

Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis.

Shaobo Zhang, Yibao Zhang, Peng Liu, Wei Zhang, Jing-Lin Ma, Jing Wang

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Clinical rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shaobo ZhangKey Laboratory of Orthopedics of Gansu Province, The Second Hospital of Lanzhou University, Lanzhou University, No. 82 Cui Ying Men Street, Lanzhou, Gansu, 730030, People's Republic of China.
Yibao ZhangKey Laboratory of Orthopedics of Gansu Province, The Second Hospital of Lanzhou University, Lanzhou University, No. 82 Cui Ying Men Street, Lanzhou, Gansu, 730030, People's Republic of China.
Peng LiuKey Laboratory of Orthopedics of Gansu Province, The Second Hospital of Lanzhou University, Lanzhou University, No. 82 Cui Ying Men Street, Lanzhou, Gansu, 730030, People's Republic of China.
Wei ZhangKey Laboratory of Orthopedics of Gansu Province, The Second Hospital of Lanzhou University, Lanzhou University, No. 82 Cui Ying Men Street, Lanzhou, Gansu, 730030, People's Republic of China.
Jing-Lin MaKey Laboratory of Orthopedics of Gansu Province, The Second Hospital of Lanzhou University, Lanzhou University, No. 82 Cui Ying Men Street, Lanzhou, Gansu, 730030, People's Republic of China.
Jing WangKey Laboratory of Orthopedics of Gansu Province, The Second Hospital of Lanzhou University, Lanzhou University, No. 82 Cui Ying Men Street, Lanzhou, Gansu, 730030, People's Republic of China. wangjing1mail@163.com.
Lanzhou University · CNLanzhou University Second Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim is to study the efficacy and safety of etoricoxib in the treatment of acute gout, as compared with non-steroidal anti-inflammatory drugs (NSAIDs). We conducted a computerized search of electronic databases: PubMed, EMBASE, Web of Science, China Biology Medicine disc, and Cochrane Library. The search terms were as follows: gout arthritis, tophus, etoricoxib, indometacin naproxen, diclofenac, and NSAIDs. Articles were searched from 1983 until August 2014. A manual search of peer-reviewed English documents was performed by cross-checking the bibliographies of selected studies. These trials reported pain relief as the primary outcome. Tenderness, swelling, patients' global assessments of response to treatment, and investigators' global assessments of response to treatment were reported as the secondary outcomes. All adverse events were recorded for safety assessment. Six trials including 851 patients were identified. Both etoricoxib and NSAIDs had an effect on inflammation and analgesia. Compared with indometacin and diclofenac, etoricoxib had a lower incidence of adverse events. Etoricoxib 120 mg administered orally once daily has the same efficacy on acute gout as indometacin and diclofenac. Etoricoxib is tolerated better by patients than NSAIDs such as indometacin and diclofenac.

Indexed as

Acute DiseaseAnti-Inflammatory Agents, Non-SteroidalCyclooxygenase 2 InhibitorsDiclofenacEtoricoxibGoutHumansIndomethacinPain MeasurementPyridinesRandomized Controlled Trials as TopicSulfonesTreatment OutcomeAnti-Inflammatory Agents, Non-SteroidalCyclooxygenase 2 InhibitorsDiclofenacEtoricoxibIndomethacinPyridinesSulfonesAcute gouty arthritisCyclooxygenase-2DiclofenacEtoricoxibIndometacinNSAID

Identifiers

PMID26099603
OpenAlexW1506625520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.